In vitro inhibition of STAT3 phosphorylation in psoriasis, Crohn's and SLE patients.

In vitro inhibition of STAT3 phosphorylation in psoriasis, Crohn's and SLE patients. - Inhibition of STAT3 phosphorylation in (auto)immune disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35388

Enrollment

Registered

2011-11-15

Start date

2011-10-25

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammatory disorders

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use local corticosteroids or ointments to prevent dry skin Crohn's: Adults (m/f) diagnosed with Crohn's disease. Patient must have experienced active disease in two years. SLE: Adults (m/f) in remission or mild flare SLEDAI

Exclusion criteria

Exclusion criteria: Psoriasis and Crohn's disease: patients have not received systemic treatment in last 2 months(methotrexate,cyclosporin A, corticosteroids, anti-TNF treatments) and no NSAIDS , iin last 6hours. SLE: Patients have a SLEDAI

Design outcomes

Primary

Measure	Time frame
- Measurement of STAT3 phosphylation in different in vitro conditions in human blood. Mainly by Facs analysis. - Inhibition of the phosphorylation by various test compounds. - Measurement of IL-23 in serum of patients.	—

Secondary

Measure	Time frame
- Expression of inflammatory mediators and surface markers in blood cells after and during pSTAT3 phosphorylation.	—

Countries

Netherlands

Outcome results